Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Drug (Brand / Generic)

Imfinzi™ / durvalumab

Developer

MedImmune, a subsidiary of AstraZeneca

Therapy Class

Monoclonal antibody (mAb)

Current Indication

Metastatic urothelial carcinoma (mUC)

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top